- Home
- RNAZ vs GSUN Comparison
RNAZ vs GSUN Comparison
Compare RNAZ & GSUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- GSUN
- Stock Information
- Founded
- RNAZ 2016
- GSUN 1997
- Country
- RNAZ United States
- GSUN China
- Employees
- RNAZ N/A
- GSUN N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- GSUN Other Consumer Services
- Sector
- RNAZ Health Care
- GSUN Real Estate
- Exchange
- RNAZ Nasdaq
- GSUN Nasdaq
- Market Cap
- RNAZ 7.2M
- GSUN N/A
- IPO Year
- RNAZ 2021
- GSUN 2022
- Fundamental
- Price
- RNAZ $0.53
- GSUN $2.87
- Analyst Decision
- RNAZ Strong Buy
- GSUN
- Analyst Count
- RNAZ 1
- GSUN 0
- Target Price
- RNAZ $20.00
- GSUN N/A
- AVG Volume (30 Days)
- RNAZ 16.6M
- GSUN 15.4K
- Earning Date
- RNAZ 05-14-2025
- GSUN 04-08-2025
- Dividend Yield
- RNAZ N/A
- GSUN N/A
- EPS Growth
- RNAZ N/A
- GSUN N/A
- EPS
- RNAZ N/A
- GSUN N/A
- Revenue
- RNAZ N/A
- GSUN $10,159,020.00
- Revenue This Year
- RNAZ $180.81
- GSUN N/A
- Revenue Next Year
- RNAZ N/A
- GSUN N/A
- P/E Ratio
- RNAZ N/A
- GSUN N/A
- Revenue Growth
- RNAZ N/A
- GSUN 65.04
- 52 Week Low
- RNAZ $0.43
- GSUN $2.21
- 52 Week High
- RNAZ $66.33
- GSUN $9.93
- Technical
- Relative Strength Index (RSI)
- RNAZ 28.52
- GSUN 46.24
- Support Level
- RNAZ $0.43
- GSUN $2.80
- Resistance Level
- RNAZ $0.61
- GSUN $3.25
- Average True Range (ATR)
- RNAZ 0.17
- GSUN 0.21
- MACD
- RNAZ 0.21
- GSUN -0.02
- Stochastic Oscillator
- RNAZ 8.24
- GSUN 24.00
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.